1st phase III trial of an ADC vs docetaxel in a biomarker selected population.Tusamitamab Ravtansine targets CEACAM5, overexpressed in 25% of non sq NSCLC.CARMEN LC03 did not meet the primary endpoints PFS and OS. #WCLC24

When you meet some of your heroes in real life ✅. #WCLC24

Nice summary slides for second line treatment for Advanced NSCLC ( non oncogene addicted) .Old studies vs New Studies . Docetaxel based therapy is hard to beat for more than a decade now. ( I don't agree that Tropion-01 is practice changing- ) #WCLC24

TIME TO CELEBRATE THE SUCCES OF #WCLC24 AND READY TO GIVE OUR BEST FOR #WCLC25. SEE YOU AT BARCELONA!!!

APOLO trial: an academic multicentric Spanish Lung Cancer Group @gecp_org presented by @MARIANOPROVENCI at #WCLC24: proof of concept of induction chemo-immunotherapy followed by radio-chemotherapy and Atezolizumab maintenance in unresectable Stage Iii NSCLC @OncoAlert

Pleased to share an updated efficacy, safety, and biomarker analysis of Larotrectinib in TRK fusion+ NSCLC, presented at the #WCLC24 today .[1/6]

At #WCLC24, @leahlphillips, a patient with stage IV EGFR lung cancer, took the opportunity to share her thoughts ahead of her upcoming surgery-and how it gives her HOPE for the future 🤍🫁🎗️.#MedTwitter #onctwitter #cancer #lungcancer #lcsm

Still in awe and inspired by all the amazing #WomeninThoracicOncology 🤩 recognized at the podium and presenting their work at #WCLC24

After @IASLC #WCLC24 in San Diego & @myESMO in Barcelona, heading to Geneva @uicc #WCC2024. Tomorrow we will present a #treatment that increases cancer #survival by years, is free accessible effective for all stages!. YES it exists #smoking #cessation. Wednesday 2pm, Plenary F

Congratulations to Dr. Linda Martin for a phenomenal presentation about Alliance trial AFT-46. This was a yearslong, painstaking cooperative group effort to study neoadjuvant durva plus chemo for operable stage IIIA/B (N2) NSCLC. Complete pathCR was 26%. #WCLC24

Not often you get home from #WCLC24 and go through one of the talks with your children. But have done just that with this outstanding presentation from Pamela Ling about vaping, cannabis and risk of lung cancer (whole PL05 session from Monday was superb). #LCSM

Following the latest CROWN data, those w ALK lung cancer want to understand what resistance to first line Lorlatinib looks like & any next 2L therapy. While the data is not quite there, Dr. @JessicaJLinMD shared this initial info from #WCLC24. The ALKtALK replay out soon. #LCSM

New strategies in Stage Iii NSCLC: moving to induction chemo-immunotherapy at #WCLC24 @OncoAlert

Lung Ca Highlights #WCLC24 w/ @GlopesMd @SylvesterCancer . - #CM77T vs #CM816.- #SKIPPirr.- #HARMONi2.- #TROPIONLung01. Full Int: .- - - Also on the “Oncology Brothers” podcast . #lcsm #OncTwitter #MedTwitter @TargetedOnc @IASLC

#WCLC24 Highlights #CommunityOncology: . 1. #HARMONi2 in mNSCLC . 2. #CM77TvsCM816 resectable NSCLC . 3. #TROPIONLung01 in 2L mNSCLC . 4. #SKIPPirr: AEs for Amivantamab. 5. #TNM staging: 9th Ed. 6. Personal highlights. #lcsm #OncTwitter @IASLC . 1/7

🫁 “INDIRECT unresectable EGFR-m stage III NSCLC 🫁. 🫁 LAURA and POLESTAR 🫁. 🫁 Osimertinib and Aumolertinib 🫁. 📌 LAURA (N Engl J Med 2024;391:585-597). 📌 Aumolertinib (#WCLC24, #PL04.13). @NEJM.#WCLC24.@IASLC.#egfr.#LCSM

New targeted therapies with TKIs for HER2 mutant NSCLC y presented at #WCLC24: the case for Zongertinib @OncoAlert

Found this in my drafts…. I was having so much fun at #WCLC24

STRENGTH. RESILIENCE. ADVOCACY. 🤍🫁🎗️.@jillfeldman4 @leahlphillips @LindiCampbell64 #WCLC24

Now that there is buzz in town for bispecifics after the showdown by ivonescimab in #WCLC24 . Here is some summary of data of approved Bispecifics updated till may 2024 ,and upcoming data , taken from @Nature reviews . It should be useful for quick reference of bispecific